



## **Antengene to Attend the H.C. Wainwright 27th Annual Global Investment Conference**

Shanghai and Hong Kong, PRC, September 4, 2025 — Antengene Corporation Limited ( **"Antengene"** , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that **Dr. Jay Mei, Antengene's Founder, Chairman and CEO, will attend the H.C. Wainwright 27th Annual Global Investment Conference to be held on September 8-10, 2025, at the Lotte New York Palace Hotel in New York City, the United States. Dr. Mei will be available for one-on-one meetings throughout the event and will be providing an update on the company's R&D progress as well as its strategic plans in a featured fireside chat.**

### **One-on-One Meetings:**

**Time:** September 8th to 10th, 2025 (Monday to Wednesday)

**Investors who would like to take a meeting are welcome to contact H.C. Wainwright directly or book a meeting through H.C. Wainwright's event portal. We look forward to connecting with attendees to exchange insights on biotech industry trends, explore new opportunities for growth and collaboration, and work together to accelerate the industry's dynamic growth and innovation.**

### **Fireside Chat:**

**Time:** September 10, 2025, Wednesday, 11:30 am – 12:00 pm Eastern Time

### **About Antengene**



Antengene Corporation Limited ( “**Antengene**” , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national reimbursement schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

### **Forward-looking statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements



are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.